Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.
Carrero-Gras A, Antela A, Muñoz-Rodríguez J, Díaz-Menéndez M, Viciana P, Torrella-Domingo A, Sanz-Moreno J, Téllez-Molina MJ, Moreno J, Hernández-Quero J, Pérez-Hernández IA, Domingo-Pedrol P. Carrero-Gras A, et al. Among authors: antela a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19819. doi: 10.7448/IAS.17.4.19819. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397563 Free PMC article.
[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002].
Rubio R, Berenguer J, Miró JM, Antela A, Iribarren JA, González J, Guerra L, Moreno S, Arrizabalaga J, Clotet B, Gatell JM, Laguna F, Martínez E, Parras F, Santamaría JM, Tuset M, Viciana P. Rubio R, et al. Among authors: antela a. Enferm Infecc Microbiol Clin. 2002 Jun-Jul;20(6):244-303. doi: 10.1016/s0213-005x(02)72804-8. Enferm Infecc Microbiol Clin. 2002. PMID: 12084354 Review. Spanish.
[Spanish recommendations for proper use of enfuvirtide].
Ribera E, Moreno S, Viciana P, Echevarría S, Flores J, Francés A, Gómez-Sirvent JL, González J, Hernández-Quero J, Lozano F, Mallolas J, Muñoz A, Ocampo A, Portilla J, Pulido F, Rivero A, Santos J, Soriano V, Antela A, Arazo P, Arribas JR, Cervantes M, Domingo P. Ribera E, et al. Among authors: antela a. Enferm Infecc Microbiol Clin. 2007 Feb;25(2):131-42. doi: 10.1157/13098573. Enferm Infecc Microbiol Clin. 2007. PMID: 17288910 Review. Spanish.
The future of antiretroviral therapy: challenges and needs.
Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F; HIV 2020 Project. Moreno S, et al. J Antimicrob Chemother. 2010 May;65(5):827-35. doi: 10.1093/jac/dkq061. Epub 2010 Mar 12. J Antimicrob Chemother. 2010. PMID: 20228080 Review.
Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses.
Yebra G, de Mulder M, Martín L, Rodríguez C, Labarga P, Viciana I, Berenguer J, Alemán MR, Pineda JA, García F, Holguín A; Cohort of the Spanish AIDS Research Network (CoRIS). Yebra G, et al. J Clin Microbiol. 2012 Feb;50(2):407-13. doi: 10.1128/JCM.05798-11. Epub 2011 Dec 7. J Clin Microbiol. 2012. PMID: 22162552 Free PMC article.
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.
Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M, The Toral Study Group. Podzamczer D, et al. Among authors: antela a. Curr HIV Res. 2012 Dec;10(8):673-8. doi: 10.2174/157016212803901428. Curr HIV Res. 2012. PMID: 23061598
Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort.
Suárez-García I, Sobrino-Vegas P, Tejada A, Viciana P, Ribas M, Iribarren J, Díaz Menéndez M, Rivero M, Arazo P, Del Amo J, Moreno S; Cohort of the Spanish AIDS Research Network (CoRIS) study group. Suárez-García I, et al. HIV Med. 2014 Feb;15(2):86-97. doi: 10.1111/hiv.12078. Epub 2013 Sep 6. HIV Med. 2014. PMID: 24007468 Free article.
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.
Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, Vergara A, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Muñoz J, Fernandez P, Geijo P, de Castro ER, Diz J, Casado A, Torres C. Podzamczer D, et al. Among authors: antela a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19814. doi: 10.7448/IAS.17.4.19814. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397558 Free PMC article.
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group. Perez-Molina JA, et al. Among authors: antela a. Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062881 Clinical Trial.
192 results